Resonant Capital Advisors LLC Buys 9,762 Shares of Pfizer Inc. (NYSE:PFE)

Resonant Capital Advisors LLC boosted its stake in Pfizer Inc. (NYSE:PFE) by 11.1% in the 4th quarter, Holdings Channel reports. The firm owned 97,898 shares of the biopharmaceutical company’s stock after acquiring an additional 9,762 shares during the quarter. Resonant Capital Advisors LLC’s holdings in Pfizer were worth $2,818,000 at the end of the most recent reporting period.

A number of other hedge funds have also added to or reduced their stakes in the stock. Moneta Group Investment Advisors LLC boosted its stake in Pfizer by 89,592.7% during the fourth quarter. Moneta Group Investment Advisors LLC now owns 161,143,638 shares of the biopharmaceutical company’s stock valued at $8,257,000,000 after buying an additional 160,963,976 shares during the period. Norges Bank bought a new stake in shares of Pfizer during the 4th quarter valued at about $3,150,472,000. Charles Schwab Investment Management Inc. grew its holdings in shares of Pfizer by 10.9% during the third quarter. Charles Schwab Investment Management Inc. now owns 95,772,746 shares of the biopharmaceutical company’s stock worth $3,161,261,000 after purchasing an additional 9,393,992 shares in the last quarter. Morgan Stanley increased its position in shares of Pfizer by 10.3% in the fourth quarter. Morgan Stanley now owns 79,499,361 shares of the biopharmaceutical company’s stock worth $4,073,547,000 after purchasing an additional 7,419,929 shares during the last quarter. Finally, Renaissance Technologies LLC purchased a new stake in Pfizer in the first quarter valued at approximately $311,238,000. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms have commented on PFE. TD Cowen cut shares of Pfizer from an “outperform” rating to a “market perform” rating and set a $32.00 price target for the company. in a research note on Thursday, January 4th. Argus lowered shares of Pfizer from a “buy” rating to a “hold” rating in a research report on Friday, March 22nd. Guggenheim started coverage on Pfizer in a research report on Friday, February 23rd. They set a “buy” rating and a $36.00 price target on the stock. Finally, Cantor Fitzgerald reiterated an “overweight” rating and issued a $45.00 price objective on shares of Pfizer in a report on Monday. Twelve research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Hold” and an average target price of $36.88.

Pfizer Trading Up 2.2 %

Shares of Pfizer stock traded up $0.57 on Friday, hitting $25.96. The stock had a trading volume of 25,890,547 shares, compared to its average volume of 42,249,816. The stock’s 50-day simple moving average is $27.14 and its two-hundred day simple moving average is $28.74. Pfizer Inc. has a one year low of $25.23 and a one year high of $40.37. The company has a quick ratio of 0.69, a current ratio of 0.91 and a debt-to-equity ratio of 0.69. The stock has a market cap of $147.00 billion, a price-to-earnings ratio of 71.89, a PEG ratio of 1.15 and a beta of 0.61.

Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, January 30th. The biopharmaceutical company reported $0.10 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.29. The business had revenue of $14.25 billion for the quarter, compared to analyst estimates of $14.37 billion. Pfizer had a net margin of 3.62% and a return on equity of 10.88%. The company’s revenue was down 41.3% on a year-over-year basis. During the same quarter last year, the firm earned $1.14 EPS. As a group, sell-side analysts predict that Pfizer Inc. will post 2.24 EPS for the current year.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.